1052 related articles for article (PubMed ID: 25872915)
1. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
Liu L
J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
[TBL] [Abstract][Full Text] [Related]
2. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
3. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
4. N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance.
Higel F; Sandl T; Kao CY; Pechinger N; Sörgel F; Friess W; Wolschin F; Seidl A
Eur J Pharm Biopharm; 2019 Jun; 139():123-131. PubMed ID: 30905778
[TBL] [Abstract][Full Text] [Related]
5. Impact of Fc N-linked glycans on in vivo clearance of an immunoglobulin G1 antibody produced by NS0 cell line.
Kim J; Luo H; White W; Rees W; Venkat R; Albarghouthi M
MAbs; 2020; 12(1):1844928. PubMed ID: 33171078
[TBL] [Abstract][Full Text] [Related]
6. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
[TBL] [Abstract][Full Text] [Related]
7. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
8. Effects of amino acid substitutions on the biological activity of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
Aoyama M; Tada M; Tatematsu KI; Hashii N; Sezutsu H; Ishii-Watabe A
Biochem Biophys Res Commun; 2018 Sep; 503(4):2633-2638. PubMed ID: 30119885
[TBL] [Abstract][Full Text] [Related]
9. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
10. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
11. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
[TBL] [Abstract][Full Text] [Related]
12. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.
Higel F; Seidl A; Sörgel F; Friess W
Eur J Pharm Biopharm; 2016 Mar; 100():94-100. PubMed ID: 26775146
[TBL] [Abstract][Full Text] [Related]
13. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
14. Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
Branstetter E; Duff RJ; Kuhns S; Padaki R
FEBS Open Bio; 2021 Nov; 11(11):2943-2949. PubMed ID: 34355537
[TBL] [Abstract][Full Text] [Related]
15. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development.
Kaur H
Crit Rev Biotechnol; 2021 Mar; 41(2):300-315. PubMed ID: 33430641
[TBL] [Abstract][Full Text] [Related]
16. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
17. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
18. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
19. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methods.
Reusch D; Haberger M; Maier B; Maier M; Kloseck R; Zimmermann B; Hook M; Szabo Z; Tep S; Wegstein J; Alt N; Bulau P; Wuhrer M
MAbs; 2015; 7(1):167-79. PubMed ID: 25524468
[TBL] [Abstract][Full Text] [Related]
20. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
